Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

NCT02805556 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: BMS-663068
DRUG: BMS-626529

Sponsor

ViiV Healthcare

Collaborators

[object Object]